All times displayed in EST - for PST, please see the Full Event Guide

8:50 am Chair’s Opening Remarks

  • Aaron Winkler Research Fellow, Immune Tolerance Lead, Inflammation & Immunology, Pfizer, Inc.

8:59 am
Discussing Development & Clinical Implementation of Tolerizing Therapies to Successfully Navigate the Road to Regulatory Approval that is Unique to Tolerization

9:00 am Facilitating Translation of Tolerization Technologies

  • Michael Yeaman Professor of Medicine, Chief, Molecular Medicine, Director, Institute for Infection & Immunity; Lundquist Institute; Chair, Medical Sciences, Guthy-Jackson Charitable Foundation, UCLA


  • Pre-clinical data is best to specify tolerization mechanism
  • Defining clinical tolerization & durability are imperative
  • Special considerations of tolerization clinical trial design

Showcasing the Diversity of Technologies & Platforms for Antigen Delivery

9:30 am Large Molecule Drug Development for the Treatment of Myasthenia Gravis


  • Showcasing disease-specific proteins as a technology for antigen delivery
  • Discussing applications in two different indications
  • Sharing thoughts on translation to the clinic

10:00 am Harnessing the Oral Mucosa for Antigen-Specific Immunotherapy of Immune Disorders

  • Poul Sørensen Professor, Chief Scientific Officer & Co-Founder, Allero Therapeutics


  • SOMIT is a novel non-invasive oral patch approach leveraging the immune privilege of the oral cavity
  • A short-course treatment regimen is achieved by combining prolonged oromucosal antigen presentation with tolerogenic microparticles derived from probiotic bacteria
  • SOMIT is a platfom technology applicable to a wide range of immune disorders e.g. autoimmune, ADA, and allergies

10:30 am Virtual Speed Networking & Break

11:00 am Scientific Poster Session


Share and inspire your peers with your research breakthroughs in Antigen-Specific Immune Tolerance

11:30 am A Novel Tolerogenic Dendritic Cell Platform with the Potential to Present the Antigen FVIII to Induce Tolerance Against FVIII in Haemophilia A Patients


  • Presentation of a novel and patented platform for generation of tolerogenic DCs
  • Hear how the tolerogenic DCs have a potential to induce regulatory T and to reduce antigen-specific T cell responses
  • Learn how tolerogenic DCs loaded with FVIII can be used to treat haemophilia A patients who developed inhibitors

12:00 pm The PCFiT Platform: A Promising Approach for B-Cell Directed Allergy Immunotherapy


  • B-cell targeting fusion proteins (PCFiT™) elicit a potent allergen specific IgG response
  • They are devoid of sensitizing and T-cell activating activity and offer short course, high-dose AIT
  • The approach can be broadly applied to all major allergen sources, clinical proof of concept has been demonstrated

12:30 pm A Novel NanoDisc Platform for Systemic Targeting of Lymphoid Tissues and Induction of Antigen-Specific Immune Tolerance

  • James Moon Co-Founder & Chief Scientific Officer; Professor of Pharmaceutical Sciences, EVOQ Therapeutics; University of Michigan


  • Exploring how subcutaneous administration of NanoDisc targets multiple lymphoid tissues and immune system organs
  • NanoDisc carrying autoantigen induces antigen-specific Tregs and Tr1 cells
  • NanoDisc therapy exerts robust efficacy in preclinical models of Multiple Sclerosis and Type 1 Diabetes

1:00 pm Lunch Networking Break

2:00 pm A Nanoparticle Platform for Multiple Immune Tolerance Therapies

Translating Durable & Efficacious Antigen-Specific Immunotherapies into the Clinic

2:30 pm Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’ Hyperthyroidism


  • Apitopes® are designed to mimic naturally processed epitopes to restore the immune system’s natural balance (i.e. tolerance to a self-antigen)
  • ATX-GD-59 is a peptide mixture of two different, highly soluble apitopes® derived from TSH-receptor. Preclinical studies have demonstrated that ATXGD-59 has a significant impact on the anti-TSHR T cell and B cell response
  • A proof of principle study has demonstrated evidence of efficacy in the majority of patients by the reduction of the antibodies and hormones associated with Graves’ disease

3:00 pm Establishing Immune Tolerance in Multiple Sclerosis Using Peptide-Coupled Red Blood Cells


  • Development and clinical implementation of a GMP process for peptide coupling using red blood cells from individual patients
  • Review of the phase 1b trial including the clinical, safety and immunological data
  • Design and implementation of a phase 2 study for clinical proof-of-concept

3:30 pm Chair’s Closing Remarks & End of Conference